Trials / Completed
CompletedNCT00005056
Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
A Phase II Trial of Bryostatin-1 in Hypernephroma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cancer Research UK · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have progressive kidney cancer
Detailed description
OBJECTIVES: I. Determine the response rates in patients with progressive hypernephroma treated with bryostatin 1. II. Determine the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive bryostatin 1 IV over 24 hours on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. For patients with stable or responding disease after completion of course 2, treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study within 12-18 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bryostatin 1 |
Timeline
- Start date
- 1999-03-01
- Completion
- 2006-07-01
- First posted
- 2004-08-09
- Last updated
- 2013-06-26
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00005056. Inclusion in this directory is not an endorsement.